Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP.
PMID: 11685083
J Immunother (1991). 2001 Sep-Oct;24(5):408-419.

Anti-CD3/anti-CD28 monoclonal antibody-coactivated T cells (COACTs) proliferate, secrete tumoricidal cytokines, and mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. This phase I study was done to determine the safety, maximum tolerated dose, technical limits of expansion, and modulation of immune functions...

Cite
Lum LG, LeFever AV, Treisman JS, et al. Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial. J Immunother (1991). 2001;24(5):408-419
Lum, L. G., LeFever, A. V., Treisman, J. S., Garlie, N. K., & Hanson, J. P. (2001). Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(5), 408-419.
Lum, Lawrence G, et al. "Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,5 (2001): 408-419.
Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP. Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial. J Immunother (1991). 2001 Sep-Oct;24(5):408-419. PMID: 11685083.
Copy Download .nbib Format: NLM
Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Riley JP, Rosenberg SA, Parkhurst MR.
PMID: 11395636
J Immunother (1991). 2001 May;24(3):212-220.

SUMMARY: Tyrosinase has many advantages as a target antigen for the immunotherapy of patients with melanoma because it is expressed in nearly all melanoma specimens with a high degree of cellular homogeneity, and its distribution in normal tissues is...

Cite
Riley JP, Rosenberg SA, Parkhurst MR. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. J Immunother (1991). 2001;24(3):212-220
Riley, J. P., Rosenberg, S. A., & Parkhurst, M. R. (2001). Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 212-220.
Riley, John P., et al. "Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 212-220.
Riley JP, Rosenberg SA, Parkhurst MR. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. J Immunother (1991). 2001 May;24(3):212-220. PMID: 11395636.
Copy Download .nbib Format: NLM
Tumor-Dendritic Cell Fusion Technology and Immunotherapy Strategies.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Shu S, Cohen P.
PMID: 11449063
J Immunother (1991). 2001 Mar;24(2):99-100.

No abstract available.

Cite
Shu S, Cohen P. Tumor-Dendritic Cell Fusion Technology and Immunotherapy Strategies. J Immunother (1991). 2001;24(2):99-100
Shu, S., & Cohen, P. (2001). Tumor-Dendritic Cell Fusion Technology and Immunotherapy Strategies. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(2), 99-100.
Shu, Suyu, and Cohen, Peter. "Tumor-Dendritic Cell Fusion Technology and Immunotherapy Strategies." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,2 (2001): 99-100.
Shu S, Cohen P. Tumor-Dendritic Cell Fusion Technology and Immunotherapy Strategies. J Immunother (1991). 2001 Mar;24(2):99-100. PMID: 11449063.
Copy Download .nbib Format: NLM
Sustained Release of Granulocyte-Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Nguyen CL, Bui JT, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE.
PMID: 11685084
J Immunother (1991). 2001 Sep-Oct;24(5):420-429.

SUMMARY: The recent identification and molecular characterization of tumor antigens provides the opportunity to explore the rational development of peptide-based cancer vaccines. However, the response to these vaccines remains variable, and peptide-based cancer vaccines may even produce tolerance induction...

Cite
Nguyen CL, Bui JT, Demcheva M, et al. Sustained Release of Granulocyte-Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response. J Immunother (1991). 2001;24(5):420-429
Nguyen, C. L., Bui, J. T., Demcheva, M., Vournakis, J. N., Cole, D. J., & Gillanders, W. E. (2001). Sustained Release of Granulocyte-Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(5), 420-429.
Nguyen, Christophe L., et al. "Sustained Release of Granulocyte-Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,5 (2001): 420-429.
Nguyen CL, Bui JT, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Sustained Release of Granulocyte-Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response. J Immunother (1991). 2001 Sep-Oct;24(5):420-429. PMID: 11685084.
Copy Download .nbib Format: NLM
Graft-Versus-Host Alloresponses to Treat Nonlymphohematopoietic Tumors: Is There a Solid Approach?.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Sykes M.
PMID: 11449064
J Immunother (1991). 2001 Mar;24(2):101-103.

No abstract available.

Cite
Sykes M. Graft-Versus-Host Alloresponses to Treat Nonlymphohematopoietic Tumors: Is There a Solid Approach?. J Immunother (1991). 2001;24(2):101-103
Sykes, M. (2001). Graft-Versus-Host Alloresponses to Treat Nonlymphohematopoietic Tumors: Is There a Solid Approach?. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(2), 101-103.
Sykes, Megan. "Graft-Versus-Host Alloresponses to Treat Nonlymphohematopoietic Tumors: Is There a Solid Approach?." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,2 (2001): 101-103.
Sykes M. Graft-Versus-Host Alloresponses to Treat Nonlymphohematopoietic Tumors: Is There a Solid Approach?. J Immunother (1991). 2001 Mar;24(2):101-103. PMID: 11449064.
Copy Download .nbib Format: NLM
Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S.
PMID: 11449067
J Immunother (1991). 2001 Mar;24(2):114-121.

SUMMARY: Cell therapy with allogeneic donor cells mismatched for minor histocompatible (MiHC) antigens was applied to a murine mammary carcinoma (4T1) model to test the feasibility of graft versus tumor (GVT) effect against metastatic epithelial tumor cells. BALB/c mice...

Cite
Morecki S, Yacovlev E, Gelfand Y, et al. Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma. J Immunother (1991). 2001;24(2):114-121
Morecki, S., Yacovlev, E., Gelfand, Y., Uzi, I., & Slavin, S. (2001). Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(2), 114-121.
Morecki, Shoshana, et al. "Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,2 (2001): 114-121.
Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma. J Immunother (1991). 2001 Mar;24(2):114-121. PMID: 11449067.
Copy Download .nbib Format: NLM
Dendritic Cell Infiltration in Colon Cancer.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Schwaab T, Weiss JE, Schned AR, Barth RJ.
PMID: 11449069
J Immunother (1991). 2001 Mar;24(2):130-137.

We quantitatively evaluated dendritic cell (DC) infiltration in primary colorectal cancers from 44 patients and metastatic colorectal tumors from 13 patients using immunohistochemistry for the DC marker CD83, HLA-DR, and the DC activation molecules CD40 and CD86. Nearly all...

Cite
Schwaab T, Weiss JE, Schned AR, et al. Dendritic Cell Infiltration in Colon Cancer. J Immunother (1991). 2001;24(2):130-137
Schwaab, T., Weiss, J. E., Schned, A. R., & Barth, R. J. (2001). Dendritic Cell Infiltration in Colon Cancer. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(2), 130-137.
Schwaab, Thomas, et al. "Dendritic Cell Infiltration in Colon Cancer." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,2 (2001): 130-137.
Schwaab T, Weiss JE, Schned AR, Barth RJ. Dendritic Cell Infiltration in Colon Cancer. J Immunother (1991). 2001 Mar;24(2):130-137. PMID: 11449069.
Copy Download .nbib Format: NLM
Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Restifo NP.
PMID: 11395633
J Immunother (1991). 2001 May;24(3):193-194.

No abstract available.

Cite
Restifo NP. Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. J Immunother (1991). 2001;24(3):193-194
Restifo, N. P. (2001). Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 193-194.
Restifo, Nicholas P.. "Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 193-194.
Restifo NP. Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. J Immunother (1991). 2001 May;24(3):193-194. PMID: 11395633.
Copy Download .nbib Format: NLM
MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Zeng G.
PMID: 11395634
J Immunother (1991). 2001 May;24(3):195-204.

SUMMARY: The adoptive transfer of tumor-infiltrating lymphocytes (TIL) can mediate tumor regression in patients with melanoma. This finding has led to the identification and characterization of tumor-associated antigens recognized by CD8+ TIL. Several clinical trials based on the genes...

Cite
Zeng G. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. J Immunother (1991). 2001;24(3):195-204
Zeng, G. (2001). MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 195-204.
Zeng, Gang. "MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 195-204.
Zeng G. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. J Immunother (1991). 2001 May;24(3):195-204. PMID: 11395634.
Copy Download .nbib Format: NLM
Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Cho HI, Han H, Kim CC, Kim TG.
PMID: 11395640
J Immunother (1991). 2001 May;24(3):242-249.

SUMMARY: For the adoptive immunotherapy in immunodeficient bone marrow transplant recipients to prevent and treat human cytomegalovirus (HCMV)-associated diseases, HCMV-pulsed dendritic cells (DCs) were used as antigen-presenting cells for the induction of cytotoxic T lymphocytes (CTLs) specific to HCMV...

Cite
Cho HI, Han H, Kim CC, et al. Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro. J Immunother (1991). 2001;24(3):242-249
Cho, H. I., Han, H., Kim, C. C., & Kim, T. G. (2001). Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 242-249.
Cho, Hyun-Il, et al. "Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 242-249.
Cho HI, Han H, Kim CC, Kim TG. Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using Dendritic Cells In Vitro. J Immunother (1991). 2001 May;24(3):242-249. PMID: 11395640.
Copy Download .nbib Format: NLM
Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Di Modugno F, Buglioni S, Mottolese M, Del Bello D, Cascioli S, Chersi A, Santoni A, Nisticò P.
PMID: 11395637
J Immunother (1991). 2001 May;24(3):221-231.

SUMMARY: The HER2 oncogene and its relative oncoprotein, gp185HER2, a transmembrane glycoprotein belonging to the epidermal growth factor receptor family, are overexpressed in a wide range of solid tumors including breast and ovarian cancer. In patients with breast cancer,...

Cite
Di Modugno F, Buglioni S, Mottolese M, et al. Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. J Immunother (1991). 2001;24(3):221-231
Di Modugno, F., Buglioni, S., Mottolese, M., Del Bello, D., Cascioli, S., Chersi, A., Santoni, A., & Nisticò, P. (2001). Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 221-231.
Di Modugno, Francesca, et al. "Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 221-231.
Di Modugno F, Buglioni S, Mottolese M, Del Bello D, Cascioli S, Chersi A, Santoni A, Nisticò P. Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. J Immunother (1991). 2001 May;24(3):221-231. PMID: 11395637.
Copy Download .nbib Format: NLM
Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens.

Journal of immunotherapy : official journal of the Society for Biological Therapy

Lambert LA, Gibson GR, Maloney M, Barth RJ.
PMID: 11395638
J Immunother (1991). 2001 May;24(3):232-236.

Multiple clinically applicable methods have been used to induce dendritic cells (DCs) to express whole cell tumor antigens, including pulsing DCs with tumor lysate, and mixing DCs with apoptotic or live tumor cells. Herein we demonstrate, using two different...

Cite
Lambert LA, Gibson GR, Maloney M, et al. Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens. J Immunother (1991). 2001;24(3):232-236
Lambert, L. A., Gibson, G. R., Maloney, M., & Barth, R. J. (2001). Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24(3), 232-236.
Lambert, Laura A., et al. "Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens." Journal of immunotherapy : official journal of the Society for Biological Therapy vol. 24,3 (2001): 232-236.
Lambert LA, Gibson GR, Maloney M, Barth RJ. Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens. J Immunother (1991). 2001 May;24(3):232-236. PMID: 11395638.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries